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 1  GENERAL PART 
1.1 INTRODUCTION 
1.1.1 The 2,5-Dimethoxyamphetamine Derived Designer Drugs  
 
Consumption of drugs of abuse is a widespread problem in societies all over the 
world. Especially, so-called designer drugs are becoming more and more popular 
among young people. The most frequently abused drugs are amphetamine, 
methamphetamine and their derivatives, such as 3,4-methylenedioxyamphetamine 
(MDA), 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”), para-methoxy-
amphetamine (PMA), and para-methoxymethamphetamine (PMMA). However, 
during the 1990s, the illicit drug market for recreational drugs changed considerably 
with several new types of drugs appearing on the drug scene. Information about 
these new drugs is readily available and they can even easily be purchased via the 
internet.1  
One of these new classes of drugs of abuse are the 2,5-dimethoxyamphetamines. 
Typical drugs of this class are 4-bromo-2,5-dimethoxyamphetamine (DOB), 4-chloro-
2,5-dimethoxyamphetamine (DOC), 4-iodo-2,5-dimethoxyamphetamine (DOI), 2,5-
dimethoxy-4-methyl-amphetamine (DOM), 4-bromo-2,5-dimethoxymethamphetamine 
(MDOB), and 2,4,5-trimethoxyamphetamine (TMA-2). Their chemical structures are 
shown in Fig. 1.  
 
Fig. 1: Chemical structures of amphetamine-derived designer drugs. 
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 They all have in common an amphetamine structure containing two methoxy groups 
in positions 2 and 5 of the aromatic ring and a different lipophilic 4-substituent. 
MDOB as the methamphetamine analogue of DOB contains an additional methyl 
moiety at the nitrogen.  
Introducing new substituents allows the drug abusers to create “legal” products which 
are not scheduled as controlled substances. Most of the 2,5-
dimethoxyamphetamines were synthesized by Alexander Shulgin and described in 
his compilation “PIHKAL”.2 This work contains the structures of the 2,5-
dimethoxyamphetamines, their hallucinogenic potency, effects, dosage and their 
synthesis. Because of this it is relatively easy for the illicit drug producers to 
manufacture a new 2,5-dimethoxyamphetamine entity when another one is 
scheduled. The first synthesized of the studied drugs was TMA-2 in 19473 and it was 
sold under the name “Zerox”. In 1967 DOM appeared on the illicit drug market 
especially in the “hippie scene” in San Francisco under the name STP, which was 
said to stand for Serenity, Tranquility, and Peace. Street names of DOB were 
“Golden Eagle” or “LSD-25”. Although many 2,5-dimethoxyamphetamines were first 
synthesized during the 1970s, they gained increasing popularity in the late 1990s and 
the beginning of this century after the publication of “PIHKAL”. They were sold in so-
called “smart shops” alone or in mixture with other designer drugs in form of tablets, 
powder, liquids or blotters. This trend was accompanied by seizures of tablets 
containing 2,5-dimethoxyamphetamines or combinations of them with other drugs by 
the police. Because of the high abuse potential of the 2,5-dimethoxyamphetamines, 
many of them were scheduled in most countries and by the UN in the convention on 
psychotropic substances in 19714. DOB became quite popular as a drug of abuse, 
especially in Australia, Italy, and the USA5-10 At present, DOI and DOC, which are not 
scheduled in the USA, and TMA-2 are entering the illicit drug market, as indicated by 
seizures11-19 and experience reports on so-called drug information web sites 
(http//:www.erowid.org, http//:www.lycaeum.org; September 2008). Some information 
is available on pharmacological properties of the 2,5-dimethoxyamphetamines. They 
show affinity to 5-HT2 receptors and act as agonists or antagonists at different 
receptor subtypes.20-25 Because of the high potency and selectivity of DOI as 5-HT2 
receptor agonist and the fact that it was not scheduled until now and is commercially 
available, it was used in research when a selective 5-HT2 receptor agonist was 
needed.26,27  
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 The chemical structure responsible for the hallucinogen-like activity comprises a 
primary amine functionality separated from the phenyl ring by two carbon atoms, the 
presence of methoxy groups in position 2 and 5 of the aromatic ring, and a 
hydrophobic 4-substituent (alkyl, halogen, alkylthio, etc.).25 The methyl moiety in 
α-position to the nitrogen atom is reported to be responsible for increased in vivo 
potency and duration of action.25  
For some 2,5-dimethoxyamphetamines, analytical data are available.28,29 A GC/MS 
procedure was described for detection of DOB and DOM (parent compounds), and 
other amphetamine derivatives but not for the other studied drugs.30 
However, for developing toxicological screening procedures, especially in urine, it is 
a prerequisite to know the metabolism of the compounds in question, especially if 
they are excreted in urine primarily or even exclusively in form of metabolites. 
Furthermore, data on the metabolism are needed for toxicological risk assessment, 
because the metabolites may play a major role in the toxicity of a drug.  
One metabolism study in humans after intoxication related to DOB has been 
reported.31 
Besides the direct toxicity of a drug or a metabolite, inhibition of metabolizing 
enzymes could also lead to toxic effects due to possible overdoses after co-
administration of different substances which were metabolized by the same enzyme. 
Some studies about the inhibition properties of amphetamine analogues on CYP2D6 
have been published.32-36 
 
 
 
1.1.2 The Cytochrome P450 System 
 
Most drugs are metabolized by a variety of enzymes, and these metabolic processes 
can generally produce metabolites that are usually less toxic than the parent 
compound. The metabolites may also be more reactive, producing toxic effects. The 
metabolic profiling of drugs is, therefore, necessary to assess their effects and 
toxicity.37 Cytochrome P450 (CYP) enzymes are responsible for oxidative and, to a 
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 minor extent, reductive metabolic transformations of drugs, environmental chemicals 
and natural compounds. Over its long history of more than 3.5 billion years, the CYP 
superfamily of enzymes has developed remarkable versatility. The primary catalytic 
function of CYPs was identified as transfer of one oxygen atom from molecular 
oxygen into various substrates (Fig. 2). A coenzyme, cytochrome P450 
oxidoreductase (OR), is essential for CYP catalytic function, and cytochrome b5 can 
stimulate catalytic activities of some enzymes.38  
 
 
Fig. 2: The cytochrome P450 redox cycle. 
Single electron shifts are frequently responsible for the formation of reactive 
intermediates or allow the leakage of free radicals capable of causing toxicity. When 
a CYP enzyme activity is modified by induction or inhibition, the biological activity of 
the xenobiotic substrate can be altered considerably. Such effects are called drug-
drug, drug-chemical or chemical-chemical-interactions. Such interactions can modify 
the disposition of xenobiotics.39-41 CYPs are heme-containing, membrane-bound 
enzymes (“heme-thiolate proteins”) detected in both prokaryotes and eukaryotes. 
The enzymes were given their names because their complexes with carbon 
monoxide under reductive conditions show an absorbance maximum at about 
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 450 nm. In mammals the enzymes can be identified in nearly every tissue, being 
most abundantly present in the liver. The CYP superfamily has been classified in 
different families in accordance to the degree of homology of amino acid sequence in 
their protein structures. CYP enzymes having ≤ 40% homology in their amino acid 
sequence are classified in different families which are designated by Arabic numbers, 
for example, CYP1. Each family is further divided into subfamilies of enzymes. The 
enzymes within a mammalian subfamily have ≥ 55% sequence homology and are 
designated by capital letters, for example, CYP1A. An Arabic number is used for 
designating individual enzymes within a subfamily, for example, CYP1A2.39 In 
humans, 18 CYP families with 43 subfamilies and 57 CYP isoenzymes are known so 
far, of which only 3 families with 7 subfamilies and 12 CYP isoenzymes are relevant 
for drug metabolism (Fig. 3),42 namely CYP1A1, CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and 
CYP3A5.43  
 
Fig. 3: Cytochrome P450s found in humans and their relevance in xenobiotic metabolism.  
Modified according to ref.43  
Polymorphisms of clinical 
relevance 
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 The remainder is responsible for the transformation of endogenous biomolecules, for 
which reason they are called “housekeeping enzymes”. Fig. 4 illustrates the 
abundances of CYPs in human liver and their importance in xenobiotic metabolism. 
Some CYP genes are polymorphically expressed, leading to variabilities in patterns 
of drug metabolism  
 
 
Fig. 4: Relative quantities of CYPs in human liver and their relevance in drug metabolism. Left 
side: human CYP-expression in the liver. Right side: involvement in xenobiotics 
metabolism. 
Human liver derived enzyme preparations, e.g. human liver microsomes (HLM) 
contain a natural mixture of CYPs. Chemical inhibitors, immunochemical inhibitors, 
and/or correlation analyses with marker activities must be used to obtain information 
on which enzymes are performing specific biotransformations. In contrast, only a 
single active CYP is present in preparations of cDNA-expressed enzymes. Inhibitors 
and correlation analyses are not needed, because the mentioned assignments can 
be performed by direct incubation of the drug with a panel of individual CYPs. 
However, the balance of enzymes, present in vivo, is lost.38 Bacteria, yeast, 
baculovirus and several mammalian cells have been used to produce a wide range of 
catalytically active CYPs. The baculovirus system offers high-level expression of both 
the CYP and OR, and are therefore advantageous for metabolism studies of all 
kinds, especially for low turnover substrates. The development of the cDNA-bearing 
virus is relatively time-consuming and labor-intensive, but baculovirus infected insect 
cell microsomes are commercially available. However, because the enzymes are 
produced transiently in the insect host cells, exact harvest time can have a 
pronounced effect on the activity of the final preparation.44  
Identification of the human enzymes involved in the metabolism of specific drugs is 
becoming increasingly important for drug development. Such identifications should 
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 consider two processes involving the new drug: metabolism and inhibition. The 
identification of enzymes involved in metabolism of the new drug allows prediction, 
based on knowledge of the ability of co-administered drugs to inhibit the same 
enzymes, of which co-administered drugs may inhibit the metabolism of the new 
drug. This information can also be used to predict individual variability based on 
known metabolic polymorphisms.38 However, also the new drug can act as an 
inhibitor what may lead to interactions with co-administered drugs. 
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 1.2 AIMS AND SCOPES 
In clinical cases where an unknown substance was ingested (e.g. poisonings), the 
identity of this substance has to be clarified to be able to start suitable medical 
treatment and to make statements on the clinical outcome. Also in forensic cases, 
intake of an illegal drug has to be proven. Usually, a general unknown screening is 
performed in urine, where the concentrations of the parent compound/and or its 
metabolites are higher than in blood or plasma and the taken drugs or toxicants can 
be detected for several hours or even days after ingestion, in contrast to blood 
analysis which covers only a few hours.45,46 Knowledge about metabolic steps is a 
prerequisite for developing toxicological screening procedures, especially, if the 
compounds are excreted in urine only in form of their metabolites. 
The knowledge of the involvement of particular CYP isoenzymes in the 
biotransformation of a new drug is a prerequisite to predict possible drug-drug-
interactions, inter-individual variations in pharmacokinetic profiles and increased 
appearance of side effects and serious poisonings.47,48 Inhibition capabilities for CYP 
isoenzymes by new drugs are also sources for drug-drug-interactions which should 
be examined. However, such risk assessment is typically performed for substances 
intended for therapeutic use, but not for drugs of the illicit market. In addition, there is 
good evidence that genetic variations in drug metabolism have important behavioral 
consequences that can alter the risk of drug abuse and dependence.49 The 2,5-
dimethoxyamphetamines were not yet investigated in any of these respects, so that 
the aims of the presented studies were: 
 
• Identification of the metabolites 
• Development of a urine screening procedure 
• Identification of the cytochrome P450 isoforms involved in the main metabolic 
steps 
• Determination of the inhibition potentials on cytochrome P450 2D6 
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 2 PUBLICATIONS OF THE RESULTS 
The results of the studies were published in the following papers: 
 
2.1 DESIGNER DRUGS 2,5-DIMETHOXY-4-BROMO-AMPHETAMINE (DOB) AND 
2,5-DIMETHOXY-4-BROMO-METHAMPHETAMINE (MDOB): STUDIES ON 
THEIR METABOLISM AND TOXICOLOGICAL DETECTION IN RAT URINE USING 
GAS CHROMATOGRAPHIC/MASS SPECTROMETRIC TECHNIQUES50 
(DOI:10.1002/JMS.1007) 
- 9 -
 
  
2.2 DESIGNER DRUG 2,4,5-TRIMETHOXY-AMPHETAMINE (TMA-2): STUDIES ON 
ITS METABOLISM AND TOXICOLOGICAL DETECTION IN RAT URINE USING GAS 
CHROMATOGRAPHIC/MASS SPECTROMETRIC TECHNIQUES51 
(DOI:10.1002/JMS.1059) 
- 23 -
 
  
2.3 METABOLISM AND TOXICOLOGICAL DETECTION OF THE DESIGNER DRUG 4-
IODO-2,5-DIMETHOXY-AMPHETAMINE (DOI) IN RAT URINE USING GAS 
CHROMATOGRAPHY-MASS SPECTROMETRY52 
(DOI:10.1016/J.JCHROMB.2007.06.027) 
- 35 -
 
  
2.4 DESIGNER DRUG 2,5-DIMETHOXY-4-METHYL-AMPHETAMINE (DOM, STP): 
INVOLVEMENT OF THE CYTOCHROME P450 ISOENZYMES IN FORMATION OF 
ITS MAIN METABOLITE AND DETECTION OF THE LATTER IN RAT URINE AS 
PROOF OF A DRUG INTAKE USING GAS CHROMATOGRAPHY-MASS 
SPECTROMETRY53 
(DOI:10.1016/J.JCHROMB.2007.11.042) 
- 43 -
 
  
2.5 METABOLISM AND TOXICOLOGICAL DETECTION OF THE DESIGNER DRUG         
4-CHLORO-2,5-DIMETHOXYAMPHETAMINE IN RAT URINE USING GAS 
CHROMATOGRAPHY-MASS SPECTROMETRY54  
(DOI:10.1007/S00216-008-1917-Z) 
- 51 -
 
  
2.6 2,5-DIMETHOXYAMPHETAMINE-DERIVED DESIGNER DRUGS: STUDIES ON 
THE IDENTIFICATION OF CYTOCHROME P450 (CYP) ISOENZYMES 
INVOLVED IN FORMATION OF THEIR MAIN METABOLITES AND ON THEIR 
CAPABILITY TO INHIBIT CYP2D655 
(DOI:10.1016/J.TOXLET.2008.09.014) 
- 59 -
  
 3 CONCLUSIONS 
The studies presented here show that the 2,5-dimethoxyamphetamine designer 
drugs DOB, DOC, DOI, MDOB, and TMA-2 were mainly metabolized by O-
demethylation, and in case of DOM by hydroxylation. Further steps were the side 
chain hydroxylation and the oxidative deamination. As metabolic phase II reactions 
partial glucuronidation and sulfation were observed. Furthermore, combinations of 
these steps as well as minor metabolites were also detected.50-53,55 
The developed screening procedures allowed the detection of the studied 2,5-
dimethoxyamphetamine in rat urine after administration of common drug abusers' 
doses mainly via their metabolites.  
In vitro studies showed that CYP2D6 was the only isoform catalyzing the 
demethylation of the DOB, DOC, DOI, MDOB, and TMA-2 and the hydroxylation of 
DOM. Besides the drugs were substrates of CYP2D6 inhibition properties on 
CYP2D6 could also be observed.53,55 
This detailed knowledge of the metabolic steps of designer drugs and the inhibition 
potential on CYP2D6 is an important prerequisite for assessing possible interaction 
with other drugs or food ingredients as well as inter-individual pharmacogenetic 
differences. These pharmacogenetic differences due to poor or ultra rapid 
metabolizers are shown especially by CYP2D6 which is polymorphically expressed. 
Besides CYP2D6 is the only enzyme catalyzing the studied metabolic steps and is 
also inhibited by the drugs, this enzyme is involved in metabolism of many 
pharmaceuticals so the possibility of drug-drug interaction is given but unlikely due to 
the high inhibition constants of the drugs. Whether these possible interactions are of 
clinical relevance can not be concluded at the moment. However, further clinical 
studies would be necessary to predict the risk of interactions. Also studies on the 
pharmacology and toxicology of the metabolites together with well documented 
clinical data will be necessary.  
- 87 -
  
 4 SUMMARY 
In the presented studies, the metabolism and the toxicological analysis in urine of the 
amphetamine-derived designer drugs DOB, DOC, DOI, DOM, MDOB and TMA-2 
were investigated. Furthermore, CYP isoform dependence of the main metabolic 
steps and the inhibition potential of the parent drugs on CYP2D6 were elucidated to 
predict possible drug-drug interactions and influence of genetic polymorphisms. The 
2,5-dimethoxyamphetamines were mainly metabolized by O-demethylation in 
position 2 and 5 of the ring, respectively, and by deamination followed by reduction to 
the corresponding alcohol. A further metabolic step was the hydroxylation of the side 
chains. Phase II reactions consisted of partial glucuronidation and/or sulfation. 
Combinations of these steps could also be detected. The target analytes for the 
toxicological analysis were the derivatized hydroxy metabolite of DOM or the O-
demethyl metabolites of DOB, DOC, DOI, MDOB and TMA-2. CYP2D6 was identified 
to be the only CYP isoform involved in the main metabolic steps. In addition, the 
studied drugs act also as inhibitor of CYP2D6. It could be shown, that the mode of 
inhibition of none of the studied drugs was irreversible, but competitive for all drugs. 
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 6 ABBREVIATIONS 
DOB 4-bromo-2,5-dimethoxyamphetamine 
DOC 4-chloro-2,5-dimethoxyamphetamine 
DOI 4-iodo-2,5-dimethoxyamphetamine 
DOM 2,5-dimethoxy-4-methylamphetamine 
MDOB 4-bromo-2,5-dimethoxymethamphetamine 
TMA-2 2,4,5-trimethoxyamphetamine 
CYP cytochrome P450 
GC-MS gas chromatography-mass spectrometry 
LC-MS liquid chromatography-mass spectrometry 
FAD flavin adenine dinucleotide 
5-HT 5-hydroxytryptamine (serotonin) 
cDNA copy deoxyribonucleic acid 
Km substrate concentration at half of the maximal turnover rate 
MDA 3,4-methylenedioxyamphetamine 
MDMA 3,4-methylenedioxymethamphetamine 
OR oxidoreductase 
PMA para-Methoxyamphetamine 
PMMA para-Methoxymethamphetamine 
Vmax maximal turnover rate 
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 7 ZUSAMMENFASSUNG 
Im Rahmen dieser Dissertation wurden der Metabolismus und die Nachweisbarkeit 
der neuen Designerdrogen des Amphetamin-Typs DOB, DOC, DOI, DOM, MDOB 
und TMA-2 im Urin untersucht. Um mögliche Interaktionen oder Einflüsse 
genetischer Polymorphismen abzuschätzen, wurde darüber hinaus untersucht, 
welche Cytochrom P450 (CYP) Isoenzyme die Hauptmetabolismusschritte 
katalysieren und ob die Drogen CYP2D6 inhibieren können. Die 2,5-
Dimethoxyamphetamine wurden hauptsächlich durch O-Demethylierung in Position 2 
bzw. 5 des Ringes oder durch Deaminierung gefolgt von Reduktion zum 
entsprechenden Alkohol metabolisiert. Weitere Metabolismusschritte waren die 
Seitenkettenhydroxylierung. Als Phase-II-Reaktionen konnten partielle 
Glucuronidierung oder Sulfatierung gefunden werden. Metabolite aus Kombinationen 
dieser Schritte konnten ebenso detektiert werden. Die derivatisierten Metabolite der 
Drogen aus den Hauptstoffwechselwegen (O-Demethylierung bei DOB, DOC, DOI, 
MDOB und TMA-2; Hydroxylierung bei DOM) waren die Zielsubstanzen im 
toxikologischen Nachweisverfahren. Für CYP2D6 konnte als einzige Cytochrom 
P450 Isoform eine Beteiligung an den Hauptstoffwechselwegen nachgewiesen 
werden. Neben der Verstoffwechselung der untersuchten Substanzen durch 
CYP2D6 konnten auch eine Hemmung dieses Enzyms durch diese Substanzen 
beobachtet werden. Es wurde gezeigt, dass keine der untersuchten Substanzen eine 
irreversible sondern eine kompetitive Hemmung bewirkte.  
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